Becton, Dickinson and Company (BDX)

240.02 +3.52 (+1.49%) At close: 04:00PM EDT

Becton, Dickinson and Company

1 Becton Drive
Franklin Lakes, NJ 07417-1880
United States
201 847 6800
https://www.bd.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 70,000

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Thomas E. Polen Jr.	President, CEO & Chairman	3.46M	N/A	1973
Mr. Christopher J. DelOrefice	Executive VP & CFO	1.6M	N/A	1971
Ms. Shana Carol Neal	Executive VP & Chief People Officer	1.79M	N/A	1966
Mr. Michael Garrison	Executive VP & President of Medical segment	1.73M	N/A	1970
Mr. Thomas J. Spoerel	Senior VP, Controller & Chief Accounting Officer	N/A	N/A	1979
Ms. Elizabeth McCombs	Executive VP & Chief Technology Officer	N/A	N/A	1976
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.	Senior VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board	N/A	N/A	N/A
Ms. Denise Russell Fleming	Executive VP of Technology & Global Services and Chief Information Officer	N/A	N/A	1970
Mr. Greg Rodetis	Head of Investor Relations	N/A	N/A	N/A
Ms. Michelle Quinn	Executive VP & General Counsel	N/A	N/A	1969

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Corporate Governance

Becton, Dickinson and Company’s ISS Governance QualityScore as of October 1, 2024 is 3. The pillar scores are Audit: 7; Board: 4; Shareholder Rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.